PropertyValue
?:abstract
  • The December 2019 outbreak of a novel respiratory virus, SARS-CoV-2, has become an ongoing global pandemic due in part to the challenge of identifying symptomatic, asymptomatic, and pre-symptomatic carriers of the virus. CRISPR diagnostics can augment gold-standard PCR-based testing if they can be made rapid, portable, and accurate. Here, we report the development of an amplification-free CRISPR-Cas13a assay for direct detection of SARS-CoV-2 from nasal swab RNA that can be read with a mobile phone microscope. The assay achieved ∼100 copies/μL sensitivity in under 30 min of measurement time and accurately detected pre-extracted RNA from a set of positive clinical samples in under 5 min. We combined crRNAs targeting SARS-CoV-2 RNA to improve sensitivity and specificity and directly quantified viral load using enzyme kinetics. Integrated with a reader device based on a mobile phone, this assay has the potential to enable rapid, low-cost, point-of-care screening for SARS-CoV-2.
is ?:annotates of
?:creator
?:doi
  • 10.1016/j.cell.2020.12.001
?:doi
?:journal
  • Cell
?:license
  • no-cc
?:pdf_json_files
  • document_parses/pdf_json/ae8d0c1ce1b202e81efd8f88b4cf36046afd3898.json
?:pmc_json_files
  • document_parses/pmc_json/PMC7834310.xml.json
?:pmcid
?:pmid
?:pmid
  • 33306959.0
?:publication_isRelatedTo_Disease
?:sha_id
?:source
  • Elsevier; Medline; PMC
?:title
  • Amplification-free detection of SARS-CoV-2 with CRISPR-Cas13a and mobile phone microscopy
?:type
?:year
  • 2021-01-21

Metadata

Anon_0  
expand all